The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Open accessAbstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%–80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year. For the past decade, doublet chemotherapy with gemcitabine and cisplatin has been considered the most effective first‐line regimen, but results from the recent use of triplet regimens and even immunotherapy may shift the paradigm. More effective treatment strategies, including those that combine systemic therapy with locoregional therapies like radioembolization or hepatic artery infusion, have also been developed. Molecular therapies, including those that target fibroblast growth factor receptor and isocitrate dehydrogenase, have recently received US Food and Drug Administration approval for a defined role as second‐line treatment for up to 40% of patients harboring these actionable genomic alterations, and whether they should be considered in the first‐line setting is under investigation. Furthermore, as the oncology field seeks to expand indications for immunotherapy, recent data demonstrated that combining durvalumab with standard cytotoxic therapy improved survival in patients with ICC. This review focuses on the current and future strategies for ICC treatment, including a summary of the primary literature for each treatment modality and an algorithm that can be used to drive a personalized and multidisciplinary approach for patients with this challenging malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
The blood supply of neoplasms in the liver.
Breedis, C., & Young, G. P. (2003) · PubMed · Cited by 1,290
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Cholangiocarcinoma: A Spectrum of Intrahepatic, Perihilar, and Distal Tumors
Nakeeb, A., Pitt, H. A., Sohn, T. A., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,187
Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V., Borad, M. J., Bridgewater, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,116
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., Wan, X., Liu, G., Wu, D., Shi, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.5984 · Cited by 1,057
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 969
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Endo, I., Gonen, M., Yopp, A. C., Dalal, K. M., Zhou, Q., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Fong, Y., Schwartz, L., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 865
Mavros, M. N., Economopoulos, K. P., Alexiou, V. G., & Pawlik, T. M. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.5137 · Cited by 808
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 786
Cholangiocarcinoma: Epidemiology and risk factors
Khan, S. A., Tavolari, S., & Brandi, G. (2019) · Liver International · doi:10.1111/liv.14095 · Cited by 783
Clinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
de Jong, M. C., Nathan, H., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6519 · Cited by 729
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 693
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El-Serag, H. B., La Vecchia, C., & Negri, E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.013 · Cited by 648
Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., Kemeny, N. E., O'Reilly, E. M., El-Dika, I., Jarnagin, W. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0078 · Cited by 582
Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.-P., Boudjema, K., Fartoux, L., Bouhier-Leporrier, K., Jouve, J.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00050 · Cited by 541
Welzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Zhu, A. X., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3836 · Cited by 509
Worldwide trends in mortality from biliary tract malignancies
Patel, T. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-10 · Cited by 491
Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2710 · Cited by 472
Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0270 · Cited by 468
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
Patel, A. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00744-3 · Cited by 425
Sapisochin, G., Facciuto, M., Rubbia‐Brandt, L., Marti, J., Mehta, N., Yao, F. Y., Vibert, E., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 370
Izquierdo-Sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klümpen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.010 · Cited by 349
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz‐Sarvisé, M., & Lamarca, A. (2019) · Liver International · doi:10.1111/liv.14086 · Cited by 326
Morizane, C., Okusaka, T., Mizusawa, J., Katayama, H., Ueno, M., Ikeda, M., Ozaka, M., Okano, N., Sugimori, K., Fukutomi, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz402 · Cited by 322
Molecular Pathogenesis of Cholangiocarcinoma
Labib, P. L., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 310
Tao, R., Krishnan, S., Bhosale, P. R., Javle, M. M., Aloia, T. A., Shroff, R. T., Kaseb, A. O., Bishop, A. J., Swanick, C. W., Koay, E. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3778 · Cited by 309
Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3702 · Cited by 306
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012
Florio, A. A., Ferlay, J., Znaor, A., Ruggieri, D., Alvarez, C. S., Laversanne, M., Bray, F., McGlynn, K. A., & Petrick, J. L. (2020) · Cancer · doi:10.1002/cncr.32803 · Cited by 304
Lunsford, K. E., Javle, M., Heyne, K., Shroff, R. T., Abdel-Wahab, R., Gupta, N., Mobley, C. M., Saharia, A., Victor, D. W., Nguyen, D. T., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30045-1 · Cited by 298
Clinical pharmacology of hepatic arterial chemotherapy.
Ensminger, W. D., & Gyves, J. W. (1983) · PubMed · Cited by 261
Risk factors for biliary tract carcinogenesis
Chapman, R. W. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s308 · Cited by 244
Tsilimigras, D. I., Sahara, K., Wu, L., Moris, D., Bagante, F., Guglielmi, A., Aldrighetti, L., Weiss, M., Bauer, T. W., Alexandrescu, S., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.1973 · Cited by 242
Self-citationMolecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Moeini, A., Sia, D., Bardeesy, N., Mazzaferro, V., & Llovet, J. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3296 · Cited by 240
Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L. H., Klümpen, H.-J., Lohse, A. W., Nashan, B., Primrose, J., Schrum, S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1498-0 · Cited by 238
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
Sia, D., Tovar, V, Moeini, A., & Llovet, J. M. (2013) · Oncogene · doi:10.1038/onc.2012.617 · Cited by 235
Oh, D.-Y., He, A. R., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.378 · Cited by 232
Cercek, A., Boerner, T., Tan, B. R., Chou, J. F., Gönen, M., Boucher, T. M., Hauser, H. F., Do, R. K. G., Lowery, M. A., Harding, J. J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3718 · Cited by 228
Self-citationHoffmann, R.-T., Paprottka, P. M., Schön, A., Bamberg, F., Haug, A., Dürr, E.-M., Rauch, B., Trumm, C. T., Jakobs, T. F., Helmberger, T. K., et al. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0142-x · Cited by 224
Lowery, M. A., Burris, H. A., Janku, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 224
Hiley, C., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome Biology · doi:10.1186/s13059-014-0453-8 · Cited by 223
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
Bridgewater, J., Fletcher, P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02568 · Cited by 216
Intrahepatic Cholangiocarcinoma
El-Diwany, R., Pawlik, T. M., & Ejaz, A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.06.002 · Cited by 214
Welzel, T. M., Mellemkjaer, L., Gloria, G., Sakoda, L. C., Hsing, A. W., Ghormli, L. E., Olsen, J. H., & McGlynn, K. A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22283 · Cited by 195
Ibrahim, S. M., Mulcahy, M. F., Lewandowski, R. J., Sato, K. T., Ryu, R. K., Masterson, E. J., Newman, S. B., Benson, A., Omary, R. A., & Salem, R. (2008) · Cancer · doi:10.1002/cncr.23818 · Cited by 188
Sapisochin, G., de Lope, C. R., Gastaca, M., de Urbina, J. O., López-Andujar, R., Palacios, F., Ramos, E., Fabregat, J., Castroagudín, J. F., Varo, E., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000494 · Cited by 185
Serum and Bile Markers for Cholangiocarcinoma
Nehls, O., Gregor, M., & Klump, B. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828891 · Cited by 180
Gabr, A., Riaz, A., Johnson, G. E., Kim, E., Padia, S., Lewandowski, R. J., & Salem, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04976-8 · Cited by 165
Ouyang, G., Liu, Q., Wu, Y., Liu, Z., Lu, W., Li, S., Pan, G., & Chen, X. (2021) · Cancer · doi:10.1002/cncr.33476 · Cited by 161
Kiefer, M. V., Albert, M., McNally, M., Robertson, M., Sun, W., Fraker, D., Olthoff, K., Christians, K., Pappas, S., Rilling, W., et al. (2011) · Cancer · doi:10.1002/cncr.25625 · Cited by 160
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
Park, S.-Y., Kim, J. H., Yoon, H.-J., Lee, I., Yoon, H., & Kim, K.-P. (2011) · Clinical Radiology · doi:10.1016/j.crad.2010.11.002 · Cited by 152
Datta, J., Narayan, R. R., Kemeny, N. E., & D'Angelica, M. I. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1694 · Cited by 151
Yao, K., Jabbour, S. K., Parekh, N., Lin, Y., & Moss, R. A. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0527-z · Cited by 147
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma
Dhanasekaran, R., Hemming, A. W., Zendejas, I. R., George, T. J., Nelson, D. R., Soldevila‐Pico, C., Firpi, R. J., Morelli, G., Clark, V., & Cabrera, R. (2013) · Oncology Reports · doi:10.3892/or.2013.2290 · Cited by 144
Vogl, T. J., Naguib, N. N. N., Nour-Eldin, N.-E. A., Bechstein, W. O., Zeuzem, S., Trojan, J., & Gruber‐Rouh, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.26407 · Cited by 144
Phelip, J., Desrame, J., Edeline, J., Barbier, E., Terrebonne, E., Michel, P., Perrier, H., Dahan, L., Bourgeois, V., Akouz, F. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00679 · Cited by 141
Kim, Y., Moris, D., Zhang, X., Bagante, F., Spolverato, G., Schmidt, C. R., Dilhoff, M. E., & Pawlik, T. M. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24720 · Cited by 135
Self-citationHepatobiliary Cancers, Version 2.2014
Benson, A. B., D'Angelica, M. I., Abrams, T. A., Are, C., Bloomston, M., Chang, D. T., Clary, B. M., Covey, A. M., Ensminger, W. D., Iyer, R. V., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0112 · Cited by 131
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis
Iavarone, M. A., Piscaglia, F., Vavassori, S., Galassi, M., Sangiovanni, A., Venerandi, L., Forzenigo, L. V., Golfieri, R., Bolondi, L., & Colombo, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.013 · Cited by 124
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Rizzo, A., & Brandi, G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100354 · Cited by 121
Spolverato, G., Bagante, F., Weiss, M. J., Alexandrescu, S. T., Marques, H. P., Aldrighetti, L. A., Maithel, S. K., Pulitanò, C., Bauer, T. W., Shen, F., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24569 · Cited by 113
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
Yadav, S., Xie, H., Riaz, I. B., Sharma, P., Durani, U., Goyal, G., Borah, B. J., Borad, M. J., Smoot, R. L., Roberts, L. R., et al. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.03.023 · Cited by 113
Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma
Zhang, X., Chakedis, J. M., Bagante, F., Chen, Q., Beal, E. W., Lv, Y., Weiss, M. J., Popescu, I., Marques, H. P., Aldrighetti, L. A., et al. (2018) · British journal of surgery · doi:10.1002/bjs.10827 · Cited by 106
Zhou, R., Lu, D., Li, W., Tan, W., Zhu, S., Chen, X., Min, J., Shang, C., & Chen, Y. (2019) · HPB · doi:10.1016/j.hpb.2018.12.011 · Cited by 103
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
Brandi, G., Farioli, A., Astolfi, A., Biasco, G., & Tavolari, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4539 · Cited by 99
Current status of liver transplantation for cholangiocarcinoma
Goldaracena, N., Gorgen, A., & Sapisochín, G. (2017) · Liver Transplantation · doi:10.1002/lt.24955 · Cited by 99
Staging cholangiocarcinoma by imaging studies
Vilgrain, V. (2008) · HPB · doi:10.1080/13651820801992617 · Cited by 98
Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
Gad, M. M., Saad, A. M., Faisaluddin, M., Găman, M., Ruhban, I. A., Jazieh, K., Al‐Husseini, M. J., Simons-Linares, C. R., Sonbol, M. B., & Estfan, B. N. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.03.024 · Cited by 96
Intrahepatic Cholangiocarcinoma
Brown, K. M., Parmar, A. D., & Geller, D. A. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.10.004 · Cited by 94
Kemeny, N. E., Schwartz, L. H., Gönen, M., Yopp, A. C., Gültekin, D. H., D'Angelica, M. I., Fong, Y., Haviland, D., Gewirtz, A. N., Allen, P. J., et al. (2011) · Oncology · doi:10.1159/000324704 · Cited by 89
Self-citationCirculating Tumor DNA Profiling of Advanced Biliary Tract Cancers
Mody, K., Kasi, P. M., Yang, J.-D., Surapaneni, P. K., Bekaii‐Saab, T., Ahn, D. H., Mahipal, A., Sonbol, M. B., Starr, J. S., Roberts, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00324 · Cited by 88
Nakachi, K., Konishi, M., Ikeda, M., Mizusawa, J., Eba, J., Okusaka, T., Ishii, H., Fukuda, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy004 · Cited by 87
Kang, S., Hwang, S., Lee, Y. J., Kim, K., Ahn, C., Moon, D., Ha, T., Song, G., Jung, D., & Lee, S. (2018) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.543 · Cited by 82
Precision medicine in cholangiocarcinoma
Pellino, A., Loupakis, F., Cadamuro, M., Dadduzio, V., Fassan, M., Guido, M., Cillo, U., Indraccolo, S., & Fabris, L. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.07.02 · Cited by 81
Larribère, L., & Martens, U. M. (2021) · Cancers · doi:10.3390/cancers13225698 · Cited by 80
Kim, S., Lee, C. H., Kim, B. H., Kim, W. B., Yeom, S. K., Kim, K. A., & Park, C. M. (2012) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e3182706562 · Cited by 79
Altekruse, S. F., Petrick, J. L., Rolin, A. I., Cucinelli, J. E., Zou, Z., Tatalovich, Z., & McGlynn, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120574 · Cited by 79
Liver transplantation for unresectable colorectal liver metastases: A systematic review
Moris, D., Tsilimigras, D. I., Chakedis, J. M., Beal, E. W., Felekouras, E. S., Vernadakis, S., Schizas, D., Fung, J. J., & Pawlik, T. M. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24671 · Cited by 79
Self-citationStereotactic body radiotherapy: A critical review for nonradiation oncologists
Kirkpatrick, J. P., Kelsey, C. R., Palta, M., Cabrera, A. R., Salama, J. K., Patel, P. R., Perez, B. A., Lee, J., & Yin, F.-F. (2013) · Cancer · doi:10.1002/cncr.28515 · Cited by 77
Self-citationZhou, S., Xin, H., Sun, R., Zhou, Z., Hu, Z., Luo, C., Wang, P., Li, J., Fan, J., & Zhou, J. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.5679 · Cited by 72
Mason, M. C., Massarweh, N. N., Tzeng, C.-W. D., Chiang, Y., Chun, Y. S., Aloia, T. A., Javle, M. M., Vauthey, J., & Cao, H. S. T. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09536-w · Cited by 68
Moris, D., Kostakis, I. D., Machairas, N., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220527 · Cited by 66
Self-citationMontazeri, S. A., la Garza‐Ramos, C. D., Lewis, A. R., Lewis, J. T., LeGout, J. D., Sella, D. M., Paz‐Fumagalli, R., Devcic, Z., Ritchie, C. A., Frey, G. T., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05776-y · Cited by 58
Jolissaint, J. S., Soares, K. C., Seier, K. P., Kundra, R., Gönen, M., Shin, P. J., Boerner, T., Sigel, C., Madupuri, R., Vakiani, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0412 · Cited by 55
Cucchetti, A., Cappelli, A., Mosconi, C., Zhong, J., Cescon, M., Pinna, A. D., & Golfieri, R. (2017) · Liver International · doi:10.1111/liv.13382 · Cited by 53
Holster, J. J., Hassnaoui, M. E., Franssen, S., IJzermans, J. N. M., de Jonge, J., Mostert, B., Polak, W. G., de Wilde, R. F., Homs, M. Y. V., & Koerkamp, B. G. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11439-x · Cited by 50
Creasy, J. M., Napier, K. J., Reed, S. A., Zani, S., Wong, T. Z., Kim, C., Wildman‐Tobriner, B., Strickler, J. H., Hsu, S. D., Uronis, H. E., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08972-y · Cited by 46
Self-citationMartin, R. C. G., Simo, K. A., Hansen, P., Rocha, F. G., Philips, P., McMasters, K. M., Tatum, C. M., Kelly, L. R., Driscoll, M., Sharma, V. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11932-3 · Cited by 45
Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Woods, E., Le, D. T., Jakka, B. K., & Manne, A. (2022) · Cancers · doi:10.3390/cancers14092137 · Cited by 44
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100356 · Cited by 43
Kim, G. H., Kim, P. H., Kim, J. H., Kim, P. N., Won, H. J., Shin, Y. M., & Choi, S. H. (2021) · European Radiology · doi:10.1007/s00330-021-08216-x · Cited by 39
Progress in Radiotherapy for Cholangiocarcinoma
Wang, N., Huang, A., Kuang, B., Yu, X., Xiao, Y., & Ma, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.868034 · Cited by 38
Csoma, S. L., Bedekovics, J., Veres, G., Árokszállási, A., András, C., Méhes, G., & Mokánszki, A. (2022) · Cancers · doi:10.3390/cancers14010233 · Cited by 35
Aitcheson, G. A., Mahipal, A., & John, B. V. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1900821 · Cited by 32
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
Fiste, O., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2021) · Vaccines · doi:10.3390/vaccines9050422 · Cited by 27
Chen, C., Wang, T., Yang, M., Song, J. T., Huang, M., Bai, Y., & Su, H. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609879 · Cited by 21
Pietge, H., Sánchez‐Velázquez, P., Akhoundova, D., Siebenhüner, A. R., Winder, T., Bachmann, H., Nguyen‐Kim, T. D. L., Breitenstein, S., Knuth, A. K., Petrowsky, H., et al. (2021) · Oncology · doi:10.1159/000512967 · Cited by 15
Cited by
Zhang, H., Dong, X., Ding, X., Liu, G., Yang, F., Song, Q., Sun, H., Chen, G., Li, S., Li, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04613-6 · Cited by 31
Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma
Deng, S., Lu, X., Wang, X., Liang, B., Xu, H., Yang, D., Cui, G., Yonemura, A., Paine, H., Zhou, Y., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06839-8 · Cited by 2
Metadata
- Authors
- Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2022-10-19
- Volume
- 73
- Issue
- 2
- Pages
- 198-222
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W4306803151
- Cited by
- 451
- References
- 110
- FWCI
- 86.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.